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Muscle precursor cells (MPCs) are activated satellite cells capable of muscle fiber reconstruction. Therefore, 
autologous MPC transplantation is envisioned for the treatment of muscle diseases. However, the density of 
MPCs, as well as their proliferation and differentiation potential, gradually declines with age. The goals of 
this research were to genetically modify human MPCs (hMPCs) to overexpress the peroxisome proliferator- 
activated receptor g coactivator (PGC-1a), a key regulator of exercise-mediated adaptation, and thereby to 
enhance early skeletal muscle formation and quality. We were able to confirm the sustained myogenic pheno-
type of the genetically modified hMPCs. While maintaining their viability and proliferation potential, PGC-1a-
modified hMPCs showed an enhanced myofiber formation capacity in vitro. Engineered muscle tissues were 
harvested 1, 2, and 4 weeks after subcutaneous injection of cell–collagen suspensions, and histological analysis 
confirmed the earlier myotube formation in PGC-1a-modified samples, predominantly of slow-twitch myofi-
bers. Increased contractile protein levels were detected by Western blot. In summary, by genetically modifying 
hMPCs to overexpress PGC-1a, we were able to promote early muscle fiber formation in vitro and in vivo, 
with an initial switch to slow-type myofibers. Therefore, overexpressing PGC-1a is a novel strategy to further 
enhance skeletal muscle tissue engineering.
Key words: Human muscle precursor cells (hMPCs); Differentiation; Skeletal muscle tissue engineering; 
Peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α)
INTRODUCTION
Damage or loss of skeletal muscles is a major con-
cern in many diseases. Autologous stem cell therapy is on 
the doorstep to successful clinical application and repre-
sents a novel treatment option for various muscle-related 
pathologies, including urinary incontinence1, vocal cord 
dysfunction2, and vesicoureteral reflux3. Satellite cells are 
quiescent cells, residing underneath the basal lamina of 
skeletal muscle fibers. They get activated after muscle tis-
sue injury, turning into proliferating myoblasts or muscle 
precursor cells (MPCs). MPCs grant sufficient progeny 
for tissue repair4,5. Because of their potential to form new 
contractile myotubes, these cells are being investigated 
for muscle tissue engineering and reconstruction in the 
treatment of a variety of muscle disorders6–9.
Despite recent progress in the field of muscle tissue bio-
engineering, a decreased proliferative capacity of MPCs 
due to donor age remains the main shortcoming of this 
approach10–12. This challenge for autologous cell therapy 
may be addressed by exercise and/or therapeutic regulation 
of gene expression, which enhances the ability of MPCs 
to restore muscle fibers. The transcriptional coactivator 
peroxisome proliferator-activated receptor g coactivator 
1a (PGC-1a) is a key player in neuromuscular activity of 
skeletal muscle and regulates important exercise-mediated 
adaptations13,14. The PGC-1a expression in a muscle is 
proportional to the amount of exercise and protects skel-
etal muscle cells from atrophy, thereby being beneficial for 
cell survival15. It serves as a transcriptional coactivator 
of nuclear receptors and transcription factors, which play 
essential roles in the regulation of cellular differentiation, 
development, and metabolism (carbohydrate, lipid, and 
protein) of higher organisms15,16. Hence, PGC-1a is regu-
lating the mitochondrial biogenesis and is adapting the 
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oxidative state in muscles14. Increase in PGC-1a levels 
goes along with a shift in the myofiber composition toward 
high-endurance muscle fibers that are capable of sus-
taining long-term contractions17. Slow-twitch myofibers 
mostly use oxygen as an electron acceptor to generate 
energy [i.e., adenosine triphosphate (ATP)], which is grad-
ually released for sustained, long contractions, resistant to 
fatigue18. Additionally, this high-endurance muscle pheno-
type is characterized with pronounced tissue vasculariza-
tion, increased mitochondria and myoglobin levels, and 
enhanced import of glucose, lipids, and lactate18. Similar 
changes are observed in adaptation to exercise, a process 
also mediated by PGC-1a. The therapeutic potential of 
PGC-1a in a metabolic optimization strategy is currently 
being investigated and highlights the importance of novel 
approaches for successful muscle tissue engineering19.
Muscle reconstruction using human MPCs (hMPCs) is 
a promising and feasible therapy method. However, fur-
ther improvements toward engineering of larger muscles, 
functional myofiber formation, and increased integration 
into the host tissue are needed. Our project thus aimed at 
the generation and validation of a viral vector for ectopic 
expression of PGC-1a in hMPCs in order to assess the 
therapeutic potential of in vivo bioengineering of skel-
etal muscle tissue in a mouse model. We hypothesize that 
initial overexpression of PGC-1a would improve muscle 
cell survival, myofiber formation capacity, and expres-
sion of muscle-specific proteins in the hMPCs. Moreover, 
it would induce a myofiber-type switch into slow-type 
myofibers, which are highly desirable for sphincter mus-
cle bioengineering.
MATERIALS AND METHODS
Isolation and Expansion of hMPCs
Human muscle biopsies from the M. rectus abdominis 
were randomly collected upon ethical approval by the local 
Swiss ethics institutions and after written informed consent 
of hospitalized patients undergoing abdominal surgery 
under general anesthesia. The samples were pro cessed 
according to established protocols20. Briefly, each muscle 
biopsy was first minced and digested with collagenase 
type I 0.2% (w/v; Sigma-Aldrich, St. Louis, MO, USA) 
and dispase 0.4% (w/v; Gibco, Grand Island, NY, USA). 
The enzymatic reaction was terminated with medium con-
taining 10% fetal bovine serum (FBS; HyClone®; Thermo 
Fisher Scientific, Waltham, MA, USA). Individual myofi-
bers were then liberated by rigorous pipetting and fil tered 
through a strainer with a pore size of 100 µm. After cen-
trifugation, the pellet was resuspended in culture medium, 
and the pieces of muscle fibers and dissociated cells 
were transferred into 35-mm dishes coated with collagen 
type I (1 mg/ml; BD Biosciences, Allschwil, Switzerland) 
as a preplating step. The culture medium consisted of 
Dulbecco’s modified Eagle’s medium (DMEM)/F-12 
(Gibco, Thermo Fisher Scientific), 1% penicillin/strep-
tomycin (Gibco, Thermo Fisher Scientific), 18% FBS, 
10 ng/ml human epidermal growth factor (hEGF; Sigma-
Aldrich, Buchs, Switzerland), 1 ng/ml human basic fibro-
blast growth factor (hbFGF; Sigma-Aldrich), 10 µg/ml 
human insulin (Sigma-Aldrich), and 0.4 µg/ml dexame-
thasone (0.5 µM; Sigma-Aldrich)20. After 24 h, the super-
natant containing nonadhered hMPCs was replated into 
dishes coated with collagen type I in order to reduce the 
number of contaminating fibroblasts.
Adenoviral Transduction
The AdEasy System (Agilent Technologies, Santa 
Clara, CA, USA) was used as a tool for recombinant ade-
novirus generation. N-terminal influenza hemagglutinin 
(HA)-tagged human PGC-1a was cloned into an ade-
noviral vector that codes for cytomegalovirus (CMV) 
promoter-driven green fluorescent protein (GFP). The 
expression of hPGC-1a was also under the control of a 
CMV promoter, thereby ensuring its robust, constitutive 
expression. Successful cloning was validated by sequenc-
ing, while viral transfection and expression of the fluo-
rescent reported genes were monitored by visualizing 
GFP (for the PGC-1a-expressing adenoviral vector). As 
a control for viral transfection, a GFP adenovirus was 
used. The viral titer was increased through an additional 
amplification step and quantified by fluorescence and 
bright-field microscopy (Leica fluorescence microscope; 
CTR 6000; Leica, Heerbrugg, Switzerland). The optimal 
multiplicity of infection (MOI) was determined accord-
ing to the manufacturer’s protocol (AdEasy Viral Titer 
Kit). In brief, hMPCs were plated and transduced, and 
the fluorescent-positive cells were quantified using a 
fluorescence microscope. Their number was compared to 
the total number of cells per field and the MOI; the ratio 
of the number of viral particles to cells was calculated.
An optimal transduction protocol in culture media was 
established beforehand, showing at least 90% cell sur-
vival as determined by trypan blue (Molecular Probes, 
Thermo Fisher Scientific, Paisley, UK) and WST-1 (Roche, 
Basel, Switzerland). Finally, the transduced hMPCs were 
expanded for 2 days after transfection and were subcu-
taneously (SC) injected into nude mice following ethical 
approval by the local ethics committees.
Animal Experimentation
All animal experiments were approved by the Swiss 
animal ethics committee (Veterinäramt Zürich, Licence 
No. 12-2012) and performed according to the animal ethics 
welfare law. A total of 24 nude mice (8 weeks old; female; 
Charles River Laboratories, Sulzfeld, Germany) were 
divided in two groups (GFP and PGC-1a). For the in vivo 
experiments, the hMPCs were expanded to passages 3–4. 
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Each sample contained 30 ´  106 transduced hMPCs, which 
were gently mixed with 500 µl of collagen type I car-
rier (final concentration: 2 mg/ml; BD Biosciences) and 
prepared for SC injection in the backs of nude mice21. 
Each animal received two bilateral SC injections, each 
containing 30 ´  106 hMPCs, under general isoflurane 
(Piramal Critical Care, Bethlehem, PA, USA) anesthesia, 
and the engineered tissues were harvested after 1, 2, and 
4 weeks.
Cell Characterization
After expansion of hMPCs to passage 3, they were 
transfected with the corresponding adenovirus and cul-
tured for 2 days. The cells were characterized by fluores-
cence-activated cell sorting (FACS) using the following 
primary antibodies: anti-MyoD (1:100; BD Biosciences), 
anti-myosin heavy chain [MyHC; 1:1; Developmen-
tal Studies Hybridoma Bank (DSHB), Iowa City, IA, 
USA], anti-desmin (1:50; Sigma-Aldrich), anti-sarcomeric 
a-actinin (1:200; Sigma-Aldrich), anti-CD34 (1:100; BD 
Biosciences), and anti-immunoglobulin G (IgG) isotype 
control (1:100; Santa Cruz Biotechnology, Heidelberg, 
Germany). Cyanine 3 (Cy3) anti-mouse IgG (1:1,000; 
Sigma-Aldrich) antibody was used as a secondary anti-
body. A total of 50,000 events were registered by BD 
FACSCanto flow cytometer (BD Biosciences) immedi-
ately after labeling, and the analysis was performed using 
FlowJo software v. 7.5 (Tree Star Inc., Ashland, OR USA). 
All data are expressed as percentage of maximum (% 
Max). All measurements were performed with at least 
three different human biopsies.
Additionally, the transduced hMPCs were cultured to 
70%–80% confluency, fixed with 4% paraformaldehyde 
(PFA) for 10 min at room temperature, permeabilized 
with 0.5% Triton X-100 (Sigma-Aldrich) for 7 min, 
blocked for 30 min [5% bovine serum albumin (BSA; 
Sigma-Aldrich) + 0.1% Triton X-100 in phosphate-
buffered saline (PBS)], and finally stained with anti-
desmin (1:50), anti-sarcomeric a-actinin (1:200), and 
anti-CD34 (negative control; 1:100) overnight at 4°C. 
After washing with PBS, the cells were incubated with 
Cy3 anti-mouse IgG secondary antibody (1:1,000) and 
4¢,6-diamidino-2-phenylindole (DAPI; 1:100; Sigma-
Aldrich) for 1 h at room temperature, washed again, and 
finally mounted (Dako, Glostrup, Denmark). Images 
were acquired with Leica Imager Type DM6000B 
(Leica), and exposures were normalized to unstained 
controls (secondary antibody and DAPI only).
Fiber Formation Assay
Differentiation of hMPCs into myofibers in vitro 
was performed as previously reported [fiber forma-
tion assay (FFA)]20. Briefly, hMPCs were grown to 
50% confluency in culture medium and afterward in 
differentiation medium (10% FBS) for 7–10 days until 
myofibers formed. The myofibers were fixed with ice-
cold methanol (7 min), stained with Giemsa (45–60 min; 
Kantonapotheke, Zürich, Switzerland), and air dried. 
Five high-power fields (HPF; 10´) were obtained per 
condition from cell samples from four patient biopsies, 
and the results were expressed as number of myofibers/
HPF, number of nuclei/myofiber, and number of nuclei/
HPF. The fusion rate was calculated by dividing the 
number of nuclei/myofiber by the number of nuclei/
HPF (%). A total n = 4 ´  5 HPF (20´) were analyzed. The 
imaging software “ImageJ for Microscopy” [National 
Institutes of Health (NIH), Bethesda, MD, USA] was 
used for data assessment.
Cell Viability and Proliferation
In all cases, cell numbers and viability were confirmed 
by trypan blue staining after trypsinization. To evalu-
ate proliferation and viability of the transfected cells at 
different time points, hMPCs were cultured for 6 days. 
The cell proliferation reagent WST-1 was used accord-
ing to the manufacturer’s protocol. For further confirma-
tion of cell viability, hMPCs were stained with 10 µM 
CellTrace™ calcein acetoxymethyl AM red-orange (Life 
Technologies, Paisley, UK) for 30 min at 37°C. Viable 
cells were detected using a fluorescence microscope. All 
measurements were performed in duplicates of at least 
three different human biopsies.
Immuno-/Histological Assessment
The harvested neoformed graft-derived tissues were 
embedded in cryopreservative optimum cutting temper-
ature (OCT) compound (embedding medium; Cell Path; 
VWR, Zürich, Switzerland) immediately after isolation. 
Cryostat sections were prepared (10 µm) and further pro-
cessed. Hematoxylin and eosin (H&E; Sigma-Aldrich) 
staining was performed according to the manufacturer’s 
protocol. For immunohistological analysis, the tissues 
were fixed with ice-cold methanol (MeOH; 60 min), 
per meabilized (0.5% Triton X-100; 20 min), blocked 
for 30 min (5% BSA + 0.1% Triton X-100 in PBS), and 
finally stained with anti-MyHC (1:2) overnight at 4°C. 
After washing with PBS, the tissues were incubated 
with Cy3 anti-mouse IgG secondary antibody (1:1,000) 
and DAPI (1:100) for 1 h at room temperature, washed 
again, and finally mounted (Dako). Images were acquired 
with Leica Imager Type DM6000B at exposures nor-
malized to unstained controls (secondary antibody and 
DAPI only).
Real-Time Polymerase Chain Reaction (RT-PCR) 
and Creatine Kinase (CK) Assay
For analysis of PGC-1a downstream-regulated genes 
(by RT-PCR) and CK levels [measured using the Cobas 
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c111 system (Roche Diagnostics, Basel, Switzerland) 
according to manufacturer’s protocol], the cells were 
cultured for 2 days after transfection and then transferred 
to a differentiation medium for 9 h, or until day 6, respec-
tively, and finally harvested for further assessments. For 
gene analysis of tissue, the harvested tissues were pul-
verized in liquid nitrogen and suspended in RNA lysis 
buffer. Total RNA was isolated for both, cells and tissues, 
using the SV Total RNA Isolation System Kit (Promega, 
Dubendorf, Switzerland) according to the manufac turer’s 
protocol, which includes a DNase digestion. RNA was 
reverse transcribed with random primers (high-capacity 
cDNA reverse transcription; Life Technologies). Pre-
designed primers for human PPARGC1 (Hs01016719_
m1), myosin heavy chain-1 (MyH1; Hs00428600_m1), 
desmin (Hs00157258_m1), and vascular endothelial growth 
fac tor (VEGF; Hs00900055_m1) were purchased from 
Life Technologies. Further primers were purchased from 
Microsynth (Balgach, Switzerland): human cytochrome 
c oxidase subunit 5 (hCox5b; forward primer: ATG GCT 
TCA AGG TTA CTT CGC, reverse primer: CCC TTT 
GGG GCC AGT ACA TT), human cytochrome c (hCycS; 
forward primer: CTT TGG GCG GAA GAC AGG TC, 
reverse primer: TTA TTG GCG GCT GTG TAA GAG), 
human estrogen-related receptor a (ERRa; forward 
primer: AGG GTT CCT CGG AGA CAG AG, reverse 
primer: TCA CAG GAT GCC ACA CCA TAG), human 
peroxisome proliferator-activated receptor g coactivator 
1a (hPGC-1a; forward primer: TCT GAG TCT GTA 
TGG AGT GAC AT, reverse primer: CCA AGT CGT 
TCA CAT CTA GTT CA), and human TATA-binding pro-
tein (hTBP; forward primer: CCC GAA ACG CCG AAT 
ATA ATC C, reverse primer: AAT CAG TGC CGT GGT 
TCG TG). 18S rRNA (4319413E) was used to normalize 
cDNA concentrations. For quantification, the expression 
of each gene was normalized to the 18S or hTBP expres-
sion in the corresponding sample. The entire experiment 
was repeated at least three times, and samples were ana-
lyzed in triplicate.
Gel Electrophoresis and Immunoblotting
In summary, tissues were pulverized in liquid nitrogen 
with a mortar/pestle and suspended in lysis buffer supple-
mented with a protease inhibitor cocktail (Sigma-Aldrich). 
Afterward, the samples were centrifuged for 20 min at 
13,000 rpm (17,949 ´  g rcf), and the supernatant was col-
lected for protein determination. The total protein was 
measured with the BCA protein assay kit (Thermo Fisher 
Scientific, Ecublens, Switzerland), and protein lysate 
(30–50 µg) was loaded on a 10% or 12% gel (Bio-Rad 
Laboratories, Cressier, Switzerland). Western blot was 
performed according to the manufacturer’s protocol. 
After the separated proteins were electrotransferred onto 
polyvinylidene difluoride (PVDF) membrane (Immo-
bilion-P; Millipore, Lucerne, Switzerland), the latter 
was incubated with a primary antibody at 4°C overnight 
in Tris-buffered saline (TBS; Münich, Germany), 0.1% 
Tween 20 (Sigma-Aldrich), and 5% nonfat dry milk. The 
primary antibodies used were anti-MyHC1 (1:5), anti-
MyHC (1:1), anti-desmin (1:50), anti-PGC-1a (1:1,000; 
Calbiochem, Darmstadt, Germany), anti-sarcomeric a- 
actinin (1:2,000; Sigma-Aldrich), anti-glyceraldehyde 
3-phosphate dehydrogenase (GAPDH; 1:2,500), and 
a-tubulin (1:2,000; Bioconcept, Allschwill, Switzerland). 
Finally, the membranes were washed in TBS with 0.1% 
Tween 20 for 30 min and incubated with the appropri-
ate horseradish peroxidase (HRP)-conjugated secondary 
antibody (Amersham Pharmacia Biotech, Little Chalfont, 
UK) for 1 h. The signals were detected by the ECL 
method (ECL-Kit; Amersham Pharmacia Biotech). The 
data were analyzed by the Image Studio Lite (Li-Cor, 
Hamburg, Germany) software and represented as protein 
expression relative to GAPDH.
Statistics
For statistical analysis, SPSS v22 (IBM, Armonk, NY, 
USA) was used, and graphics were drawn with GraphPad 
Prism v5.04 (GraphPad Software, Inc., La Jolla, CA, USA). 
All data were analyzed by Student’s t-tests for paired 
samples or one-way analysis of variance (ANOVA) with 
Bonferroni or Fisher’s least significant difference (LSD) 
post hoc analysis (p < 0.05 was considered significant). 
All presented data are expressed as means with corre-
sponding standard error of the mean (±SEM).
RESULTS
Generation and Establishment of Genetically 
Modified hMPCs
Adenoviral constructs containing hPGC-1a, or GFP 
only, were successfully generated and amplified for fur-
ther use in hMPCs. The expression of each gene was 
designed to be under the control of a CMV promoter in 
order to assure robust expression of the transgene. The 
transduction efficiency was confirmed by fluorescence 
imaging, as both constructs contain a green fluorophore, 
expressed under a separate CMV promoter (Fig. 1A). The 
constructs enabled detection of transduced cells both 
prior to transplantation for assessing the cell transduc-
tion efficiency and afterward on engineered muscle sec-
tions. The safety of the viral transfection was visualized 
by a cell viability assay (CaAM) (Fig. 1A, lower right) 
and further confirmed by trypan blue staining for distinc-
tion of live/dead cells (Fig. 1B), showing no significant 
differences between transfected [GFP (90.5 ± 1.97, n = 6) 
and PGC-1a (88.16 ± 5.32, n = 6)] and wild-type (WT; 
Delivered by Ingenta to: University of Basel
IP: 131.152.9.51 On: Mon, 12 Jun 2017 19:05:01
Article(s) and/or figure(s) cannot be used for resale. Please use proper citation format when citing this article including the DOI,
publisher reference, volume number and page location.
ENGINEERED hMPC_PGC-1a: FASTER MUSCLE FORMATION 1107
89.00± 3.01, n = 8) cells. The proliferation capacity of 
the WT, GFP-, and PGC-1a-overexpressing hMPCs 
was determined by a cell proliferation assay (WST-1) 
over 6 days of culturing after transduction, showing no 
significant variations between the different groups [at 
6 days: WT (2.77 ± 0.18, n = 6), GFP (3.12 ± 0.19, n = 9), 
and PGC-1a (2.59 ± 0.29, n = 12)] (Fig. 1C). Importantly, 
the designed adenoviruses did not affect the expression 
of specific muscle protein markers (sarcomeric a-actinin 
and desmin), as detected by immunofluorescence imag-
ing of hMPCs (Fig. 2A) and FACS (Fig. 2B) under cul-
turing conditions. The latter also showed expression of 
specific well-described markers for characterization of 
activated hMPCs4, as well as a significant shift in GFP 
expression levels in both transgenic groups, compared to 
untransfected WT cells (Fig. 2C). These results confirm 
the successful adenoviral transduction of hMPCs and 
their maintained cell phenotype.
PGC-1α Overexpression Facilitates Differentiation 
of hMPCs Into Myotubes In Vitro
To directly assess the role of PGC-1a in myofiber for-
mation, an in vitro hMPC differentiation experiment was 
performed. An FFA22 with untransduced (WT) GFP- and 
PGC-1a-transfected cells revealed an increased fusion 
rate in PGC-1a-overexpressing myoblasts (n = 4 ´  5 HPF) 
(Fig. 3A and B). The participation of transduced GFP+ 
cells in the myotube formation could be visualized by 
fluorescence microscopy (Fig. 3A, second row, fluores-
cence). The facilitated initial differentiation of the PGC- 
1a-overexpressing cells was further confirmed by West-
ern blot (Fig. 3C), where elevated desmin levels were 
Figure 1. PGC-1a adenoviral transfection without adverse effects on hMPCs. The successful adenoviral transduction of human 
muscle precursor cells (hMPCs) with green fluorescent protein (GFP) and peroxisome proliferator-activated receptor g coactivator 1a 
(PGC-1a) (A) did not affect the cell viability, as shown by the CaAM assay (A, lower right from the marked area). This was further 
confirmed by trypan blue staining of live/dead cells (B). Proliferation rate also did not differ between the wild type (WT) nontrans-
fected cells and the transfected hMPCs (C). Scale bars: 50 µm. Abbreviations: CaAM, calcein AM; OD, optical density; WST, prolif-
eration assay.
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detected already at day 2 after transfection after 9 h of 
differentiation.
The induction of differentiation goes hand in hand 
with an increase in metabolic activity (ATP consumption). 
To analyze this process, the intra- and extracellular cre-
atine kinase (iCK and eCK) levels were measured 2 and 
6 days after adenoviral transfection and initiation of dif-
ferentiation. The iCK levels were significantly increased 
in PGC-1a-transfected cells at day 2 compared to GFP-
transfected cells (p < 0.001) (Fig. 3D). At day 6, an overall 
increase in iCK levels in all three groups, concomitant 
with the induced differentiation, could be seen (Fig. 3D). 
Importantly, an increase in eCK levels is often associ-
ated with muscle damage, cell death, and membrane dis-
ruption23. Our results show that the viral transfection did 
not affect the viability and integrity of hMPCs and that 
the eCK levels remained low 2 and 6 days after transfec-
tion (Fig. 3E).
Efficient Elevation of PGC-1α and Downstream 
Regulated Genes Using Viral Vectors in hMPCs
Functionality of the expressed PGC-1a protein was 
validated by determination of well-described target 
genes of the coactivator in muscle cells. As expected, 
Figure 2. Adenoviral transfection did not change the hMPC phenotype. The expression of typical muscle markers [cyanine 3 (Cy3), 
red] in the transfected cells (green) was confirmed by immunocytochemistry. Nuclei were stained with 4¢,6-diamidino-2-phenylindole 
(DAPI; blue) (A). The human muscle precursor cells (hMPCs) were analyzed by fluorescence-activated cell sorting (FACS) for expres-
sion of various muscle marker proteins (B), and the successful transduction was confirmed by a shift in fluorescein isothiocyanate 
(FITC) signal (C). Scale bar: 25 µm.
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the introduction of the PGC-1a viral vector specifi-
cally elevated the corresponding gene expression level 
2 days ( p < 0.01) and 6 days ( p < 0.0001) after induc-
ing cell differentiation (Fig. 3F and G). The bioactivity 
of the construct was furthermore confirmed after 2 and 
6 days, respectively, by the induction of its target genes 
Cox5b ( p < 0.05, p < 0.01), CycS ( p < 0.001, p < 0.001), 
and ERRa ( p < 0.0001, p < 0.05), compared to the control 
cells transfected with GFP and untransduced hMPCs 
(WT) (Fig. 3H and I). These data confirm the efficiency 
of the presented PGC-1a adenoviral construct for genetic 
modification of hMPCs.
PGC-1α Triggers Early Myotube Formation In Vivo
Encouraged by our in vitro observations, we further 
evaluated the capability of transduced hMPCs to form 
Figure 3. PGC-1a-overexpressing hMPCs differentiate faster into myotubes in vitro. Fiber formation assay22 and fluorescence 
microscopy revealed successful myotube formation in wild-type (WT) human muscle precursor cells (hMPCs) and transfected cells, 
respectively (A), with an increased fusion rate in peroxisome proliferator-activated receptor g coactivator 1a (PGC-1a)-overexpressing 
cells (B). Two days after transfection, PGC-1a-overexpressing hMPCs displayed enhanced desmin protein levels (C). Intracellular 
CK (iCK) levels were significantly increased 2 days after PGC-1a transfection (D), whereas extracellular (eCK) levels remained 
unaffected (E). An overall increase in iCK levels was observed 6 days after inducing differentiation of the hMPCs (D) and eCK 
remained unchanged (E). PGC-1a gene expression levels were upregulated in hMPCs, transfected with PGC-1a adenovirus after 
2 (F) and 6 days (G) after transfection, compared to green fluorescent protein (GFP) and WT controls. PGC-1a downstream genes 
[human cytochrome c oxidase subunit 5 (hCox5b); human cytochrome c (hCycS); human estrogen-related receptor a (hERRa)] were 
upregulated in hMPCs transduced with PGC-1a, respectively (H, I). Data are presented as gene expression relative to human TATA-
binding protein (hTBP) using the ddCt method. Scale bars: 50 µm.
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ectopic muscle tissue in vivo. The tissues formed by 
subcutaneously injected hMPCs (transduced with GFP 
or PGC-1a) were harvested after 1, 2, and 4 weeks for 
analysis. The weight of the collected tissues did not differ 
significantly between the two groups [GFP and PGC-1a: 
114.9 ± 18.73 mg and 88.47 ± 15.96 mg ( p = 0.3021), 39 ± 
5.84 mg and 42.33 ± 4.76 mg ( p = 0.6814), and 19.44 ± 
2.33 mg and 22.94 ± 2.28 mg ( p = 0.3219) at 1, 2, and 
4 weeks, respectively; data not shown], although a ten-
dency for visually smaller PGC-1a tissues at 1 week was 
observed, concomitant with the enhanced differentiation 
(Fig. 4A). The typical red color of slow-twitch oxidative 
type I myofibers17 could be detected macroscopically after 
tissue pulverization with liquid nitrogen in the PGC-1a 
samples, but not in the control GFP samples after 1 week 
(Fig. 4B). The constant tissue volume decrease over 
time in the ex situ model due to myofiber formation and 
simultaneous collagen remodeling has previously been 
reported21. Histological assessment via H&E staining of 
the engineered tissue revealed earlier formation of myo-
tubes in the PGC-1a samples (already at week 1) (Fig. 4C, 
black arrows). This was further confirmed by immuno-
histological staining of the samples for MyHC, a marker 
for muscle differentiation and maturation, displaying an 
increased signal (Cy3, red) in the PGC-1a-transduced tis-
sues and more organized structures (myotubes) (Fig. 4D, 
white arrowheads). This was concomitant with an initial 
significant increase in VEGF-A gene levels ( p < 0.0001) in 
the harvested PGC-1a-overexpressing tissues (Fig. 5A). 
The PGC-1a overexpression was confirmed by RT-PCR 
( p = 0.009) (Fig. 5B). The earlier differentiation was fur-
ther confirmed by an increase in desmin ( p = 0.047) 
and MyHC1 ( p = 0.024) gene expression in the PGC-
1a-transfected samples, while GFP-transfected samples 
did not show expression at week 1 (n = 3–5) (Fig. 5C 
and D). In line with these results, at protein level, PGC-
1a-overexpressing engineered muscle tissue also indi-
cated an increase in relative expression levels of desmin 
(2.36 ± 1.32, n = 6) (Fig. 5E) and MyHC1 (2.24 ± 0.67, 
n = 4) (Fig. 5F) at week 1, compared to GFP samples. An 
increase in the expression of MyHC protein over time was 
observed (2.5 ± 0.96 at 4 weeks, n = 4) (Fig. 5G), lead-
ing to a suggestion for a PGC-1a-induced shift toward 
MyHC1-type myofibers at 1 week (Fig. 5H). Based on 
the findings above, PGC-1a-overexpressing hMPCs hold 
promise for the enhanced repair of skeletal muscle tissue 
because of their capacity to speed up myofiber formation, 
with an initial shift to oxidative type I myofibers.
DISCUSSION
Muscle tissue bioengineering has made substantial prog-
ress over the last decade, allowing us to grow functional 
muscle tissue21,24. Subcutaneous implantation of myo-
blasts may have a range of useful applications, from the 
study of myogenesis to the delivery of gene products24. 
Nevertheless, there are still substantial limitations in size 
and quality of the engineered constructs. Additionally, 
drugs including testosterone, growth hormone, leptin, 
myostatin inhibitors, creatine, and vitamin D have been 
successfully used to support muscle strength and growth25. 
Yet, there are safety concerns for their long-term applica-
tion, and therefore, more investigations are required in 
order to minimize their adverse effects. Another possible 
solution for rebuilding muscle tissues is cell therapy using 
satellite cells. The induced expression of several factors 
in MPCs has extensively been studied, mostly to obtain 
enhanced cell viability and proliferation, or to prevent apo-
ptosis and induce angiogenesis, or to induce gap junction 
formation against cardiac arrhythmias26.
Many muscle disorders are associated with skeletal mus-
cle inactivity, and exercise is an exceptional therapeutic 
mediation for many disease conditions27. Although the 
exact mechanisms mediating these healing effects still 
remain elusive, several pathways have been proposed28. 
While resistance training combined with adequate nutri-
tion remains the most effective intervention for dimin-
ishing the functional decline in muscles, there is a certain 
age-linked barrier to obtaining full benefits from this 
therapy25.
A promising molecule controlling skeletal muscle 
metabolism with potential therapeutic effect has been 
identified14. PGC-1a is a known and potent transcrip-
tion coactivator for nuclear receptors and other tran-
scription factors. It is expressed in skeletal muscles and 
is a powerful master regulator of mitochondrial biogen-
esis29. Interestingly, PGC-1a has been shown to increase 
the expression of myofiber type I fibrillar proteins by 
coactivating the myocyte enhancer factor 2 (Mef2) tran-
scription factors, thereby coordinating the expression of 
both metabolic and contractile properties of type I myo-
fibers17. These findings make PGC-1a a good candidate 
for targeted regulation of skeletal muscle cell metabo-
lism and plasticity in the myofiber formation process; 
therefore, we decided to research its applicability for the 
bioengineering of improved muscle tissues.
The ultimate goal in skeletal muscle tissue engineer-
ing is the construction of a functional tissue of a desired 
myofiber type. Interested in sphincter muscle bioengi-
neering, we aimed at improving the regenerative potential 
of hMPCs by inducing PGC-1a overexpression through 
ade noviral gene delivery. By overexpressing PGC-1a in 
hMPCs, we targeted a major crossroad of intracellular 
pathways, affecting cell metabolism (mitochondrial activ-
ity upregulation) and, simultaneously, enhancing the early 
expression of contractile proteins (MyHC1, desmin) and 
secretory factors (VEGF-A), thereby facilitating the pro-
cess of skeletal muscle bioengineering. Our data showed 
feasibility of viral overexpression of PGC-1a with desired 
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Figure 4. Engineered muscle formation is enhanced by overexpression of PGC-1a in hMPCs. Human muscle precursor cells 
(hMPCs) transduced with peroxisome proliferator-activated receptor g coactivator 1a (PGC-1a) or control green fluorescent protein 
(GFP) adenovirus were injected subcutaneously on both sides of the back of nude mice. The harvested tissue was visualized mac-
roscopically at 1 week at the subcutaneous tissue (A). The typical red color of oxidative type I myofibers was enriched in PGC-1a 
samples, compared to GFP controls (samples powderized with liquid nitrogen) (B). The process of successful myofiber formation 
was visualized over 4 weeks with hematoxylin and eosin (H&E) staining (C), revealing an increased early myotube formation in 
PGC-1a-overexpressing samples (black arrows). Tibialis anterior (TA) was used as native control for muscle fiber formation. The 
increased differentiation capacity of PGC-1a transgenic hMPCs at early time points (1 week) was also envisioned by immuno-
staining for myosin heavy chain (MyHC) [cyanine 3 (Cy3), red] of the ex situ-engineered muscle fibers (green) [4¢,6-diamidino-2-
phenylindole (DAPI), blue] (D). Scale bars: 50 µm (white), 0.5 cm (black).
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phenotypic changes in the ectopic muscle but importantly 
without detrimental side effects on hMPC viability and 
differentiation in vivo and in vitro. We acknowledge that 
the proliferation assay (WST-1) measurement is depen-
dent on mitochondrial function, and PGC-1a might mask 
the possible lack of proliferation in the transfected cells. 
However, we visualized the cell viability by CaAM assay 
and quantified it by trypan blue staining without observing 
any detrimental effects upon PGC-1a viral transfection.
The bioactivity of PGC-1a was confirmed by signifi-
cantly enhanced expression of PGC-1a downstream tar-
gets, proving the functional efficiency of the presented 
construct. Supporting evidence suggests an increased 
expression of mitochondrial and other metabolic genes 
as a plausible mechanism for rescuing a damaged mus-
cle27. Therefore, the demonstrated increase in PGC-1a 
downstream mitochondrial targets was a key milestone 
for further in vitro and in vivo studies.
A crucial role in the process of forming new muscle tis-
sue is played by the capacity of myoblasts to differentiate 
into myotubes/myofibers and a sustained energy metabo-
lism. Our genetically modified hMPCs showed a signifi-
cantly increased fusion rate, in parallel with an enhanced 
energy metabolism, depicted by iCK levels and mitochon-
drial gene level analysis. Given the low iCK levels in 
myoblasts and their increase with myotube formation, our 
results indicate that viral overexpression of PGC-1a drives 
higher iCK expression, possibly due to a faster differentia-
tion process. Moreover, elevated desmin protein expres-
sion was detected 2 days after the adenoviral transfection, 
showing the early appearance of sarcomeric architecture. 
Consistent with the observed facilitated in vitro differen-
tiation, the ectopically formed skeletal muscle tissue with 
PGC-1a overexpression revealed myotube formation and 
increased expression of contractile proteins (desmin and 
MyHC1) already after 1 week, indicating facilitated dif-
ferentiation. Interestingly, this strong effect was reduced 
at later time points. However, PGC-1a-modified samples 
expressed higher levels of general MyHC with an increase 
over time, when compared to GFP samples, while there 
was higher MyHC1 (slow twitch) protein expression at 
1 week. These data indicate a possible initial shift toward 
slow-type myofibers. Related gene delivery studies sug-
gest that overexpression of certain factors (e.g., VEGF) 
may be beneficial at the time of cell transplantation, and 
their transient effect may prevent the risk of malignancy 
formations30,31.
Vascularization of the bioengineered tissue is the 
bottleneck of many approaches. Importantly, PGC-1a-
overexpressing tissues showed enhanced VEGF-A gene 
levels. Secretion of various effectors by the injected 
hMPCs may also contribute to optimization of the regen-
erative process (e.g., increased neovascularization)21,32. 
Moreover, PGC-1a has been demonstrated to stimulate 
angiogenesis in skeletal muscle by inducing the release of 
key factors, including VEGF, in cultured muscle cells and 
skeletal muscle in vivo33. Furthermore, PGC-1a seems to 
have led to overexpression of VEGF-A, thereby prob-
ably inducing early neovascularization and counteracting 
necrosis after implantation, possibly leading to improved 
cell/tissue survival and better long-term survival. In line 
with our in vivo observations, others have shown that an 
increased VEGF release in a hypoxic environment leads to 
enhanced differentiation34. This could explain the observed 
increase in contractile MyHC protein and myofiber forma-
tion in PGC-1a-engineered tissues, when compared to the 
corresponding GFP samples.
Whether the accelerated differentiation seen in this 
research using an ex situ model really leads to functional 
improvement during regeneration has to be validated 
using intramuscular (IM) injection of the modified cells. 
However, the use of ectopic model for muscle tissue engi-
neering also brings along valuable information about the 
formation of muscle fibers in a nonmyogenic environ-
ment, as it might be in the patients, for example, scar tis-
sue. Considering these facts, the optimal model to study 
skeletal muscle regeneration would be to inject the cells 
in injured muscles. Further, the use of viral gene delivery 
for clinical applications is still associated with several 
drawbacks35. We acknowledge that the choice of the ade-
noviral delivery method might not be the most suitable 
one. For a clinical setup, we would suggest a nonviral 
gene delivery method. We further acknowledge a possible 
immune reaction from the mice we chose, although no 
detrimental effects were detected in the engineered tis-
sues. Still this model sets a significant milestone toward 
the possible engineering of improved muscle tissue of a 
desired myofiber type.
ACKNOWLEDGMENTS: The authors recognize the research 
efforts of those who have contributed to this field of study. Special 
thanks to Damina Balmer for the critical assessment of the manu-
script. The authors’ work is supported by grants from the Swiss 
National Science Foundation (SNF; CRSII3_136197/1), Promedica 
Foundation, and Novartis. The funders were not involved in the 
study design, collection, analysis, and interpretation of data, writ-
ing of the report, or the decision to submit the manuscript for pub-
lication. The authors declare no conflicts of interest.
REFERENCES
Tran C, Damaser MS. The potential role of stem cells in  1. 
the treatment of urinary incontinence. Ther Adv Urol. 
2015;7(1):22–40.
Halum SL, Naidu M, Delo DM, Atala A, Hingtgen CM.  2. 
Injection of autologous muscle stem cells (myoblasts) 
for the treatment of vocal fold paralysis: A pilot study. 
Laryngoscope 2007;117(5):917–22.
Murray P, Camussi G, Davies JA, Edgar D, Hengstschlager  3. 
M, Kenny S, Remuzzi G, Werner C. The KIDSTEM 
European research training network: Developing a stem 
cell based therapy to replace nephrons lost through reflux 
nephropathy. Organogenesis 2007;3(1):2–5.
Delivered by Ingenta to: University of Basel
IP: 131.152.9.51 On: Mon, 12 Jun 2017 19:05:01
Article(s) and/or figure(s) cannot be used for resale. Please use proper citation format when citing this article including the DOI,
publisher reference, volume number and page location.
1114 HARALAMPIEVA ET AL.
Hawke TJ, Garry DJ. Myogenic satellite cells: Physiology  4. 
to molecular biology. J Appl Physiol (1985) 2001;91(2): 
534–51.
Hill M, Wernig A, Goldspink G. Muscle satellite (stem)  5. 
cell activation during local tissue injury and repair. J Anat. 
2003;203(1):89–99.
Gussoni E, Soneoka Y, Strickland CD, Buzney EA, Khan  6. 
MK, Flint AF, Kunkel LM, Mulligan RC. Dystrophin 
expression in the mdx mouse restored by stem cell trans-
plantation. Nature 1999;401(6751):390–4.
Yiou R, Yoo JJ, Atala A. Restoration of functional motor  7. 
units in a rat model of sphincter injury by muscle precursor 
cell autografts. Transplantation 2003;76(7):1053–60.
Tedesco FS, Dellavalle A, Diaz-Manera J, Messina G,  8. 
Cossu G. Repairing skeletal muscle: Regenerative potential 
of skeletal muscle stem cells. J Clin Invest. 2010;120(1): 
11–9.
Peault B, Rudnicki M, Torrente Y, Cossu G, Tremblay JP,  9. 
Partridge T, Gussoni E, Kunkel LM, Huard J. Stem and 
progenitor cells in skeletal muscle development, mainte-
nance, and therapy. Mol Ther. 2007;15(5):867–77.
Stölting MN, Hefermehl LJ, Tremp M, Azzabi F, Sulser T, 10. 
Eberli D. The role of donor age and gender in the success of 
human muscle precursor cell transplantation. J Tissue Eng 
Regen Med. 2017;11(2):447–58.
Schultz E, Lipton BH. Skeletal muscle satellite cells: 11. 
Changes in proliferation potential as a function of age. 
Mech Ageing Dev. 1982;20(4):377–83.
Rando TA. Stem cells, ageing and the quest for immortality. 12. 
Nature 2006;441(7097):1080–6.
Pilegaard H, Saltin B, Neufer PD. Exercise induces tran-13. 
sient transcriptional activation of the PGC-1alpha gene in 
human skeletal muscle. J Physiol. 2003;546(Pt 3):851–8.
Handschin C. The biology of PGC-1alpha and its therapeu-14. 
tic potential. Trends Pharmacol Sci. 2009;30(6):322–9.
Sandri M, Lin J, Handschin C, Yang W, Arany ZP, Lecker 15. 
SH, Goldberg AL, Spiegelman BM. PGC-1alpha protects 
skeletal muscle from atrophy by suppressing FoxO3 action 
and atrophy-specific gene transcription. Proc Natl Acad Sci 
USA 2006;103(44):16260–5.
Rodgers JT, Lerin C, Gerhart-Hines Z, Puigserver P. 16. 
Metabolic adaptations through the PGC-1 alpha and SIRT1 
pathways. FEBS Lett. 2008;582(1):46–53.
Lin J, Wu H, Tarr PT, Zhang CY, Wu Z, Boss O, Michael 17. 
LF, Puigserver P, Isotani E, Olson EN, Lowell BB, Bassel-
Duby R, Spiegelman BM. Transcriptional co-activator 
PGC-1 alpha drives the formation of slow-twitch muscle 
fibres. Nature 2002;418(6899):797–801.
Schiaffino S, Reggiani C. Fiber types in mammalian skel-18. 
etal muscles. Physiol Rev. 2011;91(4):1447–531.
Handschin C, Mortezavi A, Plock J, Eberli D. External phys-19. 
ical and biochemical stimulation to enhance skeletal muscle 
bioengineering. Adv Drug Deliv Rev. 2015;82–83:168–75.
Eberli D, Soker S, Atala A, Yoo JJ. Optimization of human 20. 
skeletal muscle precursor cell culture and myofiber forma-
tion in vitro. Methods 2009;47(2):98–103.
Delo DM, Eberli D, Williams JK, Andersson KE, Atala A, 21. 
Soker S. Angiogenic gene modification of skeletal mus-
cle cells to compensate for ageing-induced decline in 
bioengineered functional muscle tissue. BJU Int. 2008; 
102(7):878–84.
Herzog H, Langen KJ, Weirich C, Rota Kops E, Kaffanke 22. 
J, Tellmann L, Scheins J, Neuner I, Stoffels G, Fischer K, 
Caldeira L, Coenen HH, Shah NJ. High resolution BrainPET 
combined with simultaneous MRI. Nuklearmedizin 2011; 
50(2):74–82.
Baird MF, Graham SM, Baker JS, Bickerstaff GF. Creatine-23. 
kinase- and exercise-related muscle damage implications 
for muscle performance and recovery. J Nutr Metab. 
2012;2012:960363.
Irintchev A, Rosenblatt JD, Cullen MJ, Zweyer M, Wernig A. 24. 
Ectopic skeletal muscles derived from myoblasts implanted 
under the skin. J Cell Sci. 1998;111(Pt 22):3287–97.
Rolland Y, Onder G, Morley JE, Gillette-Guyonet S, 25. 
Abellan van Kan G, Vellas B. Current and future pharma-
cologic treatment of sarcopenia. Clin Geriatr Med. 2011; 
27(3):423–47.
Ciecierska A, Chodkowska K, Motyl T, Sadkowski T. Myo-26. 
genic cells applications in regeneration of post-infarction 
cardiac tissue. J Physiol Pharmacol. 2013;64(4):401–8.
Handschin C, Spiegelman BM. The role of exercise and 27. 
PGC1alpha in inflammation and chronic disease. Nature 
2008;454(7203):463–9.
Egan B, Zierath JR. Exercise metabolism and the molecu-28. 
lar regulation of skeletal muscle adaptation. Cell Metab. 
2013;17(2):162–84.
Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant 29. 
G, Mootha V, Troy A, Cinti S, Lowell B, Scarpulla RC, 
Spiegelman BM. Mechanisms controlling mitochondrial 
biogenesis and respiration through the thermogenic coacti-
vator PGC-1. Cell 1999;98(1):115–24.
Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell 30. 
PC, Blau HM. VEGF gene delivery to myocardium: Delete-
rious effects of unregulated expression. Circulation 2000; 
102(8):898–901.
Ozawa CR, Banfi A, Glazer NL, Thurston G, Springer ML, 31. 
Kraft PE, McDonald DM, Blau HM. Microenvironmental 
VEGF concentration, not total dose, determines a threshold 
between normal and aberrant angiogenesis. J Clin Invest. 
2004;113(4):516–27.
Zimna A, Janeczek A, Rozwadowska N, Fraczek M, 32. 
Kucharzewska P, Rucinski M, Mietkiewski T, Kurpisz M. 
Biological properties of human skeletal myoblasts genetically 
modified to simultaneously overexpress the pro-angiogenic 
factors vascular endothelial growth factor-A and fibroblast 
growth factor-4. J Physiol Pharmacol. 2014;65(2):193–207.
Thom R, Rowe GC, Jang C, Safdar A, White JP, Arany Z. 33. 
Hypoxic induction of vascular endothelial growth factor 
(VEGF) and angiogenesis in muscle by N terminus peroxi-
some proliferator-associated receptor gamma coactivator 
(NT-PGC)-1alpha. J Biol Chem. 2015;290(32):19543.
Bryan BA, Walshe TE, Mitchell DC, Havumaki JS, Saint-34. 
Geniez M, Maharaj AS, Maldonado AE, D’Amore PA. 
Coordinated vascular endothelial growth factor expression 
and signaling during skeletal myogenic differentiation. Mol 
Biol Cell 2008;19(3):994–1006.
Kay MA. State-of-the-art gene-based therapies: The road 35. 
ahead. Nat Rev Genet. 2011;12(5):316–28.
